US FDA declines to approve Regeneron's blood cancer therapy-March 2024-www.financetom.com

US FDA declines to approve Regeneron's blood cancer therapy

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA declines to approve Regeneron's blood cancer therapy

Mar 25, 2024 4:29 AM

March 25 (Reuters) - Regeneron Pharmaceuticals ( REGN )

said on Monday the U.S. Food and Drug Administration has

declined to approve its blood cancer therapy for two most common

subtypes of non-Hodgkin lymphoma due to an issue related to the

enrollment status of the confirmatory trials.

(Reporting by Sneha S K, Puyaan Singh and Sriparna Roy in

Bengaluru; Editing by Shinjini Ganguli)

Previous page： Yeti expands board, adds two directors after discussions with activist Engaged Next page： AstraZeneca's Imfinzi Approved by EU for Treatment of Small Cell Lung Cancer

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Yeti expands board, adds two directors after discussions with activist Engaged

Mar 17, 2025

NEW YORK, March 17 (Reuters) - Outdoor goods company Yeti Holdings ( YETI ), which makes cooler boxes and insulated cups, on Monday said it will add two new directors and expand the size of its board after months of discussions with activist investor Engaged Capital. Magnus Welander, former chief executive of lifestyle and outdoor company Thule, and Arne Arens,...

AstraZeneca's Imfinzi Approved by EU for Treatment of Small Cell Lung Cancer

Mar 17, 2025

08:08 AM EDT, 03/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Monday its drug Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell lung cancer. The indication for the drug, also called durvalumab, is for patients whose disease has not progressed following platinum-based chemoradiation therapy, the company said. The...

Market Chatter: Bank of America Increases Oversight of Young Bankers' Workloads

Mar 17, 2025

08:04 AM EDT, 03/17/2025 (MT Newswires) -- Bank of America ( BAC ) is increasing oversight of the workloads of its younger bankers, The Wall Street Journal reported Monday. The bank said senior bankers will now be responsible for making sure junior investment bankers aren't overworked, the Journal reported. The move comes after a 35-year-old Bank of America ( BAC...

Yeti expands board, adds two directors after discussions with activist Engaged

Mar 17, 2025

NEW YORK (Reuters) - Outdoor goods company Yeti Holdings ( YETI ), which makes cooler boxes and insulated cups, on Monday said it will add two new directors and expand the size of its board after months of discussions with activist investor Engaged Capital. Magnus Welander, former chief executive of lifestyle and outdoor company Thule, and Arne Arens, former chief...